Global pharma major Lupin Limited, commonly known as Lupin, has named Shahin Fesharaki as the global chief scientific officer of the company. In his new role, Fesharaki will headline Lupin's global research and development initiatives, along with kickstarting new speciality products.
For the uninitiated, a chief scientific officer is an executive who is responsible for managing their company's scientific, technological, and research operations. These executives are employed primarily by organisations in the science and research fields.
Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin congratulated Fesharaki on his appointment and on becoming part of the leadership team.
"Shahin’s exceptional track record in delivering brands and generics across developed and emerging markets will be valuable to us as we accelerate our evolution into complex generics and specialities while driving growth across all our major markets," Vinita and Nilesh added.
Fesharaki exudes a bludgeoning portfolio in the field of drug development, with close to three decades worth of experience in leading global pharmaceutical companies. Prior to Lupin, he served as Hikma Pharmaceutical's chief scientific officer and global Head of R&D for three years.
His journey has been quite extensive with prior leadership associations with Actavis and Apotex, where he worked for close to a decade each. He started his career as a formulation specialist at Apotex and rose to the position of director, formulations development - new products within 9 years.
Fesharaki is an industry leader in the development of both generic and branded pharmaceuticals across a broad range of technologies and dosage forms. He did his Bachelor's and Masters in Pharmacy from Savitri Bai Phule University, India and did his PhD from the University of Mumbai. He will be based out of U.S.